AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06748508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
Description: Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.
Study NCT06748508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
Description: Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.
Study NCT05875506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone gel
Description: (Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
Study NCT05875506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone gel
Description: (Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
Study NCT05875506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline hyclate saturated chitosan dressing
Description: doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
Study NCT05875506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline hyclate saturated chitosan dressing
Description: doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
Study NCT06750133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Description: Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells(6-10×10\^7 CNK+ cells/kg). The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study.
Study NCT06750965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum M protein screening
Description: Using highly sensitivity test to screen serum M protein of all participants.
Study NCT05904535 — intervention group
Intervention type: OTHER
Intervention: Cerbrospinal fluid sampling.
Description: Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
Study NCT06750757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate
Description: 145cc of BMAC/PRP/PPP injection.
Study NCT06750757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Description: Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.
Study NCT06750757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip arthroscopy
Description: Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.
Study NCT06749340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Psychometric Hepatic Encephalopathy Scoring (PHES) Test~* Digit Symbol Test~* Number Combination Test-A~* Number Combination Test-B~* Serial Punctuation Test~* Line Drawing Test~  6 Minute Walk Test~  5 Times Sit and Stand Test~Manual Muscle Test~Hand Grip Strength Test~Quadriceps muscle thickness measurement with ultrasonography~All evaluations will be repeated 5 times.
Study NCT06749340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Psychometric Hepatic Encephalopathy Scoring (PHES) Test~* Digit Symbol Test~* Number Combination Test-A~* Number Combination Test-B~* Serial Punctuation Test~* Line Drawing Test~  6 Minute Walk Test~  5 Times Sit and Stand Test~Manual Muscle Test~Hand Grip Strength Test~Quadriceps muscle thickness measurement with ultrasonography~All evaluations will be repeated 5 times.
Study NCT06749340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face Exercise
Description: Participants will undergo exercise sessions 3 days a week for 12 weeks. Sessions will include a warm-up, upper and lower extremity strengthening (1/3 set - 8/12 repetitions) and cool-down program. Theraband will be used in strengthening exercises. Theraband offers different resistance levels with its different colors. In order from lightest to heaviest; skin color, yellow, red, green, blue, black, grey, gold. Exercises (theraband color, intensity, number of sets and repetitions) will be made into a personalized program according to the tolerance level of the participants in the first session. Exercise intensity will be determined using the OMNI - Resistance Exercise Scale (OMNI - RES). The warm-up and cool-down periods in the exercise program will be carried out at levels 9 - 12 according to the Borg Scale.
Study NCT06749340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Participants will follow the same program as in the face-to-face exercise group. The first meeting with the participants will be held face to face and the details of the study will be explained. Home-based exercises will be carried out with the Fiziu (Fiziu Sağlık Hizmetleri Teknoloji A.Ş., Istanbul, Türkiye) program and the exercise program will be delivered to the participants through this program. Therabands with which the participants will do their exercises will be provided by the researchers. The progression program will be determined in line with the difficulty and effort felt by the participants through weekly meetings.
Study NCT06749340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants assigned to the control group will have the same evaluation sessions as participants assigned to the experimental groups. The first evaluation will be made at the beginning of the study, the second evaluation after the 8-week period, the third evaluation after the 12-week period, the fourth evaluation after the 6-month follow-up, and the fifth evaluation after the 12-month follow-up. Participants who will not be included in any study sessions during this process will be included in the study program that appears to be effective as a result of the study. Participants in this group will be offered the program recommended by the US Office of Disease Prevention and Health Promotion and used in individuals who have previously had a liver transplant. This program consists of aerobic exercises (walking, cycling, etc.) starting from 60-65% of the maximum heart rate and progressing to 75-80%.
Study NCT06748716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Description: The investigators hypothesize that blue-blocking glasses (intervention) is more effective than placebo.
Study NCT06748716 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clear glasses
Description: Clear-lensed glasses are placebo
Study NCT06751407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single level SPSIPB
Description: The procedure will be performed with the patient in the prone position in the preoperative period. After the scapula is slightly shifted laterally, the US probe is held sagittally at the upper corner of the scapula spine, and the 3rd rib and the serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and entered between the serratus posterior superior and the 3rd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be used.
Study NCT06751407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-level SPSIPB
Description: In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 2nd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 10 ml of 0.25% bupivacaine will be used. Then, the US probe will be held sagittally in the medial part of the scapula spine, and the 4th rib and serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 4th rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block site is confirmed, 10 ml of 0.25% bupivacaine will be used. A total of 20 ml of 0.25% bupivacaine will be used.
Study NCT06749509 — intervention group
Intervention type: OTHER
Intervention: Face-to-face musculoskeletal rehabilitation
Description: Kela's rehabilitation course for those with MSD includes two 5-day periods and one 3-day period of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation center over a 9-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation course is group-based and provided free of charge. The 9-month rehabilitation period also includes calls to the participants before and after rehabilitation. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A medical statement is required when applying for the rehabilitation course.
Study NCT06749509 — intervention group
Intervention type: OTHER
Intervention: Musculoskeletal telerehabilitation
Description: Kela´s MSD telerehabilitation course is arranged entirely as telerehabilitation, and it includes videoconferencing, online rehabilitation, and group-based rehabilitation days implemented by a multidisciplinary team of rehabilitation experts. Participation does not require particular IT skills, but appropriate equipment (e.g., mobile phone, laptop, tablet computer) is needed. The rehabilitation course is free of charge, and the total duration, including the calls before and after rehabilitation, is approximately 7 months. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A physiotherapist's recommendation is required when applying for the telerehabilitation course
Study NCT06749509 — intervention group
Intervention type: OTHER
Intervention: Controls
Description: The control participants have an MSD diagnosis and musculoskeletal symptoms. Based on an occupational physiotherapist's brief evaluation they are eligible to apply for Kela's musculoskeletal rehabilitation (the interventions below). By them own choice, however, they will not participate in these rehabilitation programs in the near future. The controls are recruited via two occupational health care producers in the private sector.
Study NCT04461210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermographic Imaging and Mechanical Pain Assessment
Description: Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
Study NCT06496997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
Study NCT06496997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone at an equivalent dose of 13 mg/day
Study NCT06496997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone at an equivalent dose of 350 mg/day
Study NCT04569435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: IV Infusion
Study NCT04925427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management and Peer Recovery
Description: A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
Study NCT04925427 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Naloxone-Only
Description: Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
Study NCT05121896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan
Description: 7.0 tesla functional MRI scan
Study NCT05746793 — intervention group
Intervention type: PROCEDURE
Intervention: endometrium biopsy
Description: The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle.
Study NCT05746793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transabdominal ultrasound
Description: Evaluation of fetal biometry and doppler flow study using ultrasound.
Study NCT03889834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Transfusion
Description: Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
Study NCT03889834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No transfusion
Description: no transfusion
Study NCT05447806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support
Description: This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
Study NCT03998319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase (1/3 systemic weight based dose)
Description: 50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
Study NCT03998319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water for injection (WFI)
Description: Placebo comparative arm.
Study NCT06221969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.
Study NCT06221969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.
Study NCT06221969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide will be administered subcutaneously.
Study NCT04973098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT0181 Cells
Description: 5 dose levels each with or without lymphocyte clearance were tentatively determined.
Study NCT05746793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral phlebotomy
Description: single puncture collection of peripheral venous blood.
Study NCT05911256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Only
Description: Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
Study NCT05911256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist Only
Description: Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
Study NCT05911256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
Study NCT05911256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)
Description: Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
Study NCT05929911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychodynamic psychotherapy
Description: This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands.
Study NCT05746793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection
Description: Collection of urine in a plastic cup.
Study NCT06087432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rocabado's 6x6 Exercises
Description: Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
Study NCT05746793 — intervention group
Intervention type: OTHER
Intervention: MOCK frozen embryo transfer preparative cycle.
Description: Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
Study NCT05746793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline questionnaire
Description: questionnaire the patient has to fill in
Study NCT06087432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado's 6x6 Exercises
Description: Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.